What happened
Meinian Health (002044.SZ) reported 2026 first-half operating revenue of 3.844 billion yuan, with more than 210 million yuan of that main-business revenue coming from AI-integrated services.
The company attributed parts of the slower first-half period to seasonal factors, including holiday distribution and corporate financial planning cycles that pushed some budgets and examination appointments to later in the year. It said order signing remained relatively stable and that business affected by the pace of visits would be released in the second half.
By the end of the period, its 'Health Xiaomei' AI chief-examination system covered 394 examination centers and had generated more than 16 million reports, while an ultrasound AI voice agent was live in 224 centers and shortened average examination and report-writing times.
Why it matters
The results offer an early sign that Meinian Health's 'All in AI' strategy can contribute measurable revenue, as AI tools are embedded in diagnosis, quality control and service delivery to improve doctor efficiency and accuracy.
With AI-assisted offerings such as pancreatic tumor risk assessment rolled out in 296 branches and new AI-focused products for aging evaluation, the company is pushing beyond standard physical exams toward a platform-based health management model.
Key facts
H1 2026 operating revenue was 3.844 billion yuan, with AI-related main-business revenue exceeding 210 million yuan.
The 'Health Xiaomei' AI system covered 394 centers and generated over 16 million reports, while the ultrasound AI voice agent was live in 224 centers.
Pancreatic tumor risk assessment was offered in 296 branches, using Alibaba DAMO Academy's DAMO-PANDA model on low-dose plain CT scans.
What to watch next
Whether deferred corporate demand shows up in the second half as Meinian Health expects, especially during the traditional peak physical-examination season.
How further AI adoption affects operating costs, report quality and customer experience, and whether new products such as lung cancer methylation and AI aging assessment gain traction.
Progress in emerging areas like longevity medicine, weight management, oral health, traditional Chinese medicine and precision nutrition, which the company sees as potential second-curve growth.